1.
Clin Case Rep
; 9(5): e03164, 2021 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34094551
RESUMO
Bosutinib is a tyrosine kinase inhibitor approved for the management of chronic myeloid leukemia (CML). Interstitial lung disease and pleural effusion are pulmonary side effects of TKIs rarely associated with bosutinib treatment.